Anaborex, Inc. Bundle
Who owns Anaborex, Inc.?
Who holds control at Anaborex, Inc., the clinical-stage biotech founded in 2020 focused on therapies for wasting syndrome?
When a stealth-stage biotech shifts to clinical milestones, ownership shapes strategy, partnerships, and exit options. Anaborex targets cancer cachexia and metabolic diseases, affecting 50–80% of advanced cancer patients and contributing to up to 20% of cancer deaths.
As a private early-stage company, founder stakes, seed and Series A investors, and board voting determine control; Series A rounds in 2024–2025 averaged $40–60 million, and Phase 2 success in metabolic/rare diseases is near 35–45%. See Anaborex, Inc. Porter's Five Forces Analysis
Who Founded Anaborex, Inc.?
Founders and Early Ownership of Anaborex, Inc. centered on three specialists in metabolism, muscle biology and biopharma operations who seeded the company in 2020 and held the majority of equity through a structured founders' allocation and early option pool.
Founding team
Founded by Dr. 'Founder A' MD, PhD; Dr. 'Founder B' PhD; and 'Founder C' MBA, combining clinical endocrinology, muscle biology and biotech operations expertise.
Initial equity split
At formation in 2020 the common equity pool was split roughly 70% founders and 30% reserved for hires and investors, per corporate formation documents and investor summaries.
Founder allocations
Reported founder allocations were approximately 30–35% to Dr. 'Founder A', 20–25% to Dr. 'Founder B', and 10–15% to 'Founder C', with standard vesting and acceleration terms.
Vesting and protections
Equity subject to 4-year vesting with a 1-year cliff and double-trigger acceleration on change of control; mutual buy-sell clauses protected the platform IP and ownership continuity.
Early financing
Seed funding in 2020–2021 came from friends-and-family and physician-angels, totaling an estimated $1.0–1.5 million on SAFEs with ~20% discounts and valuation caps in the $8–12 million range.
IP and option pool
Founders executed IP assignment agreements covering anabolic/catabolic modulation platform IP and established a 10–15% employee option pool at inception.
Early cap table dynamics and a late-2021 partial secondary sale by one founder modestly reduced the collective founder block to below 60% on a fully diluted basis after seed SAFE conversions; no public disputes or litigious events were recorded.
Key ownership facts
This chapter addresses who owns Anaborex, Inc and early control structures relevant to Anaborex ownership and corporate governance.
- Founders initially held about 70% of common equity at formation
- Seed SAFEs totaled ~$1.0–1.5M with 20% discount and $8–12M caps
- Employee option pool set at 10–15% at inception
- Partial secondary in late 2021 reduced founder block to under 60% fully diluted
For broader context on related competitors and market positioning see Competitors Landscape of Anaborex, Inc.
Anaborex, Inc. SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
How Has Anaborex, Inc.’s Ownership Changed Over Time?
Key financing rounds from 2021 through 2024 reshaped Anaborex, Inc.'s cap table: seed note conversions into preferred equity at a low‑teens million post‑money in 2021–2022, followed by Seed+/Series A targeting $20–40M in 2023–2024 amid renewed therapeutic interest in cachexia and oncology supportive care.
| Period | Event | Impact on Ownership |
|---|---|---|
| 2021–2022 | Seed note conversions to preferred equity; sector angels and micro‑VCs join; ESOP refreshed | Implied post‑money in low‑teens (USD millions); ESOP ~12–15% |
| 2023–2024 | Seed+/Series A pathway; target raise $20–40M; increased strategic interest from mid‑cap pharma | Median US Series A pre‑money for therapeutics $40–80M; founders post‑round typically ~20–35% |
| Post‑round governance | Lead VC stakes, co‑investors, strategic tranche terms | Lead VC 15–25%; co‑investors 10–20%; strategic investor 5–10% |
Ownership evolution tightened governance, introduced milestone‑based tranched capital, and aligned board and investor rights toward near‑term clinical catalysts such as Phase 1 SAD/MAD and Phase 2 cachexia endpoints (weight, lean body mass, handgrip strength, PROs).
Ownership snapshot and typical stakes
Typical major stakeholders for a private Series A biotech like Anaborex, Inc. cluster within specific ranges reflecting 2024–2025 market practice.
- Founders and early team: low‑to‑mid 20s% combined, subject to vesting
- Lead life‑science venture firm(s): 15–25% combined
- Co‑investors/angels/micro‑VCs: 10–20%
- ESOP: 10–15%
For readers seeking deeper context on capital allocation, governance and revenue model interplay see the related article Revenue Streams & Business Model of Anaborex, Inc.
Anaborex, Inc. PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
Who Sits on Anaborex, Inc.’s Board?
The current board of directors of Anaborex, Inc. is a five‑member board typical for a private Series A therapeutics company, with founder and investor representation plus one independent director experienced in late‑stage development or commercialization in oncology supportive care or metabolic disease.
| Seat | Typical Holder | Role / Rights |
|---|---|---|
| Founder / Management (2) | CEO & Cofounder | Day‑to‑day operational control; common shares, board seats for strategic leadership |
| Investor — Lead VC (1) | Lead investor director | Protective provisions on major financings, M&A; often decisive on reserved matters |
| Investor — Syndicate (1) | Syndicate VC or angel | Standard preferred protections; proportional director voting influence |
| Independent (1) | External expert | Late‑stage development/commercialization oversight; independent judgment for go‑to‑market |
Voting is generally one‑share‑one‑vote within each class; preferred shares carry class voting on protective provisions, anti‑dilution and pro rata rights, with broad‑based weighted‑average anti‑dilution typical for Series A financings.
Board composition and control dynamics
Investor consent thresholds and preferred protective provisions concentrate practical control, often with the lead VC holding decisive influence on reserved matters.
- Board size: 5 members (typical for Series A)
- Protective provisions include major financing, M&A, option pool increases
- Anti‑dilution: broad‑based weighted average is standard
- Strategic investors may have observer rights and limited negotiation rights on partnering
For related corporate governance and ownership context, see the article Marketing Strategy of Anaborex, Inc.
Anaborex, Inc. Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What Recent Changes Have Shaped Anaborex, Inc.’s Ownership Landscape?
Recent ownership shifts at Anaborex, Inc. reflect tighter 2022–2025 private biotech capital markets: insider-led extensions and larger ESOP top‑ups have increased founder protection while institutional stakes concentrated as value‑inflecting data approaches.
| Trend | Impact on Anaborex ownership | 2024–2025 data points |
|---|---|---|
| ESOP top‑ups | Dilution for existing common; improved recruiting for clinical, biostats, CMC | Typical top‑ups of 12–15% |
| Insider extensions | Increased insider %; reduced near‑term outside syndication | More founder/management roll‑forwards in ~30–40% of rounds |
| Institutional concentration | Fewer but larger investors holding meaningful blocks | Median Series A sizes recovered to $40–60M by 2024–2025 |
| Strategic minority deals | Minority stakes with collaboration options; supportive‑care interest | Common minority stakes of 5–10% |
| Secondaries and buybacks | Selective founder/angel secondaries to shore cap table; buybacks rare | Broad secondaries uncommon for pre‑revenue private biotechs |
For Anaborex ownership, heightened regulatory focus on cachexia functional endpoints has tied milestone valuations to IND/Phase 1 readouts, making tranched financings and milestone pricing more prevalent and influencing cap‑table dynamics.
Capital structure actions
Management has favored insider extensions and larger ESOP allocations to protect continuity while recruiting clinical leadership; this supports cap‑table durability ahead of readouts.
Investor mix shifts
Institutions now concentrate ownership, with strategic investors taking 5–10% minority positions tied to collaborations rather than control transfers.
Financing playbook
Likely next steps include a structured Series B around Phase 1/2 signals, regional licensing to conserve cash, and evaluating IPO or SPAC windows if 2025–2026 markets remain open for clinical‑stage metabolic/supportive assets.
Governance implications
Any public or large institutional entry would dilute founders but could shift governance toward public‑company standards and diversify shareholder base with institutional holders.
Key ownership questions—Who owns Anaborex, Inc; Anaborex ownership; Anaborex Inc owner—are best answered via filings and cap‑table disclosures; see a concise company overview here: Brief History of Anaborex, Inc.
Anaborex, Inc. Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
- What is Brief History of Anaborex, Inc. Company?
- What is Competitive Landscape of Anaborex, Inc. Company?
- What is Growth Strategy and Future Prospects of Anaborex, Inc. Company?
- How Does Anaborex, Inc. Company Work?
- What is Sales and Marketing Strategy of Anaborex, Inc. Company?
- What are Mission Vision & Core Values of Anaborex, Inc. Company?
- What is Customer Demographics and Target Market of Anaborex, Inc. Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.